69-week Weight Loss Study for People With Overweight or Obesity Without Diabetes

Written By Patrick Smith

Are you living with overweight or obesity and do not have diabetes? 

If so, you may be eligible to participate in a clinical research study evaluating an FDA-approved once-daily oral GLP-1 medicine (oral Wegovy) for weight management.

ABOUT THE STUDY

This is a Phase 3 study evaluating how oral semaglutide (oral Wegovy) affects body weight.

WHO MAY QUALIFY? 

You may be eligible to participate if you meet all the following: 

  • Age 18 years or older

  • Body mass index (BMI) of 27 or higher (classified as overweight or obesity) 

  • Do not have diabetes

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) for longer than 30 days within the past year 

  • Have never had surgery for treatment of obesity

INTERESTED IN LEARNING MORE? 

Click below to complete a short questionnaire to see if you may be eligible.
(JotForm link)

Study Sponsor: Novo Nordisk A/S

ClinicalTrials.gov ID: NCTXXXXXXXX link  

Patrick Smith
Previous

32-week Weight Loss Study for People With Obesity Without Diabetes
Next

2-year Weight Loss Study for People With Obesity Without Diabetes